Seaport Therapeutics

We're pleased to be recognized by BioSpace on its NextGen Class of 2025 list of the hottest new life science companies! Check out the full list of exciting companies already making an impact on the industry, including a nice snapshot on Seaport: https://lnkd.in/e838FJrV

Our Co-founder and Chief Executive Officer, Daphne Zohar, will present at the J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 9:30am PST / 12:30pm EST. She will be joined by Steven Paul, M.D., Co-founder and Chair of the Board of Directors, and Michael C. Chen, Ph.D., Co-founder and Chief Scientific Officer, during the Q&A portion of the presentation https://lnkd.in/eqzaDyyt

This week, we moved into our new space and celebrated our team and core values: service to patients/humility, entrepreneurial/ownership mindset, making the world a happier place, and teamwork as we reflected on Seaport’s rapid progress and growth since our launch in April. We look forward to many more moments together as we continue to advance our clinical-stage pipeline and reach our ultimate goal of delivering new medicines that will make a difference in the lives of those impacted by neuropsychiatric disorders, including depression and anxiety. 

Great list and important to recognize patient centered decisions (Amylyx). Also well-deserved shout out to my friend and colleague Steven Paul on #Cobenfy approval (and to BMS CEO for the acquisition) Best Biopharma CEO of 2024?

The New York Times article spotlighting 7 things everyone should know about antidepressants calls attention to the tremendous need for better medicines that help address unfavorable side effects, modest efficacy, & weeks delay to work for patients: https://nyti.ms/49AXN6x

This week, Antony Loebel, our Chief Medical Officer and President of Clinical Development, and Daniel Bonner, Co-founder, SVP, Platform, presented additional data from our Phase 1 study of SPT-300 at the American College of Neuropsychopharmacology (ACNP) Annual Meeting in Phoenix, Arizona. SPT-300 is an oral prodrug of allopregnanolone that is designed to retain the pharmacological activity of allopregnanolone, an endogenous neurosteroid. Allopregnanolone has been clinically validated in third-party trials as a rapidly acting antidepressant with anxiolytic effects.    New data in the poster include further safety analyses and pharmacokinetic and pharmacodynamic data. Together with previous clinical efficacy data, the further analyses of the Phase 1 study demonstrate that these doses of SPT-300 are well-tolerated and have rapidly acting pharmacodynamic activity. Based on the Phase 1 study results, the profile of SPT-300 is suitable for chronic dosing and oral administration at night in the planned Phase 2b placebo-controlled study in major depressive disorder with or without anxious distress. #ANCP2024   Read more in today’s press release: https://lnkd.in/ec-XK-fS 

Last night at the #NEVY24 awards ceremony, which recognizes the venture and innovation ecosystem, we were thrilled to be a part of the celebration recognizing Karuna Therapeutics' KarXT (now Cobenfy) as an award winner in the Patient Impact category. Members of our team were recognized for their contributions to the early scientific work and innovation that led to the invention of KarXT/Cobenfy. Eric Elenko who was one of a team of scientists who co-invented Cobenfy at PureTech Health - where Karuna was founded - accepted the award at the gala. To learn more about the history and innovation story, watch this NEVY's acceptance video featuring Seaport co-founders Daphne Zohar and Steven Paul: https://lnkd.in/eS4db5Nq We’re proud that Seaport is led by the team that was involved in inventing and advancing KarXT/Cobenfy, and we look forward to building on this proven development strategy as we advance our clinical-stage pipeline of novel neuropsychiatry medicines in areas of high unmet patient needs, including depression and anxiety.

New review in Nature Neuroscience highlights the neuroplastic activity of rapidly acting antidepressants, including allopregnanolone https://lnkd.in/ea73XXrr

We’re pleased to welcome Sandi Peterson to our Board of Directors! Ms. Peterson is a prominent and seasoned business leader with extensive experience driving innovation and operational excellence across leading global life sciences and consumer organizations. She has held a series of high-profile leadership roles over the course of her career, including serving as the lead independent director on the Microsoft Board of Directors and as the former Group Worldwide Chair for Johnson & Johnson. https://bit.ly/4hYNVHK

Earlier today, our Chief Scientific Officer, Michael C. Chen, PhD, and our Chief Medical Officer, President of Clinical Development, Antony Loebel, MD, were joined by Stifel’s Paul Matteis at the #StifelHealthcareConference to discuss Seaport’s approach to neuropsych drug development, including our Glyph platform and clinical-stage pipeline of novel therapeutics for the treatment of #depression, #anxiety and other #neuropsychiatric disorders. Listen to the webcast here: https://lnkd.in/ewqmhEjy